Drug Detail

Information about Pazopanib + Trametinib

Generic Name	Pazopanib + Trametinib
IND
Brand Name (US)
Manufacturer	GlaxoSmithKline
Drug Type	Tyrosine Kinase Inhibitor
Delivery	Oral
Approval Status	Pazopanib is approved for RCC
Indications	RCC
Overall Strategy	KIT Protein Based + Oncogenic Signal Path Based
Strategy	Block KIT + Block related tumor signal paths
Drug Category	KIT/PDGFRA inhibitor + MEK inhibitor

The combination provides a KIT inhibitor + a MEK inhibitor (trametinib). The combination of a KIT inhibitor and a MEK inhibitor shows good activitiy against GIST cells in the lab.